Heather A. Wakelee, MD, Stanford University, Stanford, CA, talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Adjuvant immune checkpoint blockade demonstrated disease-free survival (DFS) benefit with a safety profile consistent of atezolizumab monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.